切换至 "中华医学电子期刊资源库"
高级检索
中华医学超声杂志（电子版）

中华医学超声杂志（电子版） ›› 2021, Vol. 18 ›› Issue (01) : 45 -49. doi: 10.3877/cma.j.issn.1672-6448.2021.01.010

所属专题： 文献；

腹部超声影像学

经肝动脉超声造影对经肝动脉栓塞化疗治疗肝细胞癌效果的评价
韩鹏1, 罗渝昆1,†(), 费翔1, 姜波1, 王志军2, 贺崇1   
  1. 1. 100853　北京，中国人民解放军总医院第一医学中心超声诊断科
    2. 100853　北京，中国人民解放军总医院第一医学中心介入放射科
  • 收稿日期:2019-06-21 出版日期:2021-01-01
  • 通信作者: 罗渝昆
  • 基金资助:
    人工智能辅助便捷式超声对腹部实质脏器战创伤自动诊断系统的建立(2H19021)

Clinical value of transhepatic arterial contrast-enhanced ultrasonography in assessing efficacy of transarterial chemoembolization for hepatocellular carcinoma

Peng Han1, Yukun Luo1,†(), Xiang Fei1, Bo Jiang1, Zhijun Wang2, Chong He1   

  1. 1. Department of Ultrasonography, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
    2. Department of Interventional Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
  • Received:2019-06-21 Published:2021-01-01
  • Corresponding author: Yukun Luo
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

韩鹏, 罗渝昆, 费翔, 姜波, 王志军, 贺崇. 经肝动脉超声造影对经肝动脉栓塞化疗治疗肝细胞癌效果的评价[J]. 中华医学超声杂志（电子版）, 2021, 18(01): 45-49.

Peng Han, Yukun Luo, Xiang Fei, Bo Jiang, Zhijun Wang, Chong He. Clinical value of transhepatic arterial contrast-enhanced ultrasonography in assessing efficacy of transarterial chemoembolization for hepatocellular carcinoma[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2021, 18(01): 45-49.

目的

探讨经肝动脉超声造影评价经肝动脉栓塞化疗（TACE）治疗肝细胞癌（HCC）效果的临床应用价值。

方法

选取解放军总医院第一医学中心2018年9月至2019年2月因肝肿瘤行TACE治疗的38例HCC患者（共48个病灶），分别行术前及术后即刻经肝动脉超声造影，通过观察肿瘤内及引流区是否增强评估疗效，并与TACE术后1个月的MRI结果进行对比。患者经肝动脉超声造影与MRI结果采用配对资料的χ2检验，采用Kappa检验评价经肝动脉超声造影与MRI结果的一致性，并评价其诊断效能。

结果

术后即刻仅观察瘤内是否增强判断栓塞疗效与术后1个月MRI相比差异无统计学意义（P=0.289），同时观察肿瘤内及引流区是否增强判断疗效与术后1个月MRI相比差异无统计学意义（P=1.000），同时观察瘤内及引流区的评估结果一致性高于仅观察瘤内的评估结果（Kappa值：0.780 vs 0.664；P＜0.001）。同时观察瘤内及引流区的评估结果特异度为84.2%、敏感度为93.1%、准确性为89.5%，均高于仅观察瘤内的评估结果（79.3%、89.4%、83.3%）。

结论

采用经肝动脉超声造影观察HCC瘤内及引流区是否增强可以术后即刻且准确地评价TACE治疗疗效，具有较高的临床价值。

关键词: 经肝动脉超声造影, 引流区, 经肝动脉栓塞化疗, 肝细胞癌
Objective

To assess the clinical application value of transhepatic arterial contrast-enhanced ultrasonography in evaluating the therapeutic effect of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).

Methods

Thirty-eight patients with 48 lesions of HCC underwent TACE at the First Medical Center of Chinese PLA General Hospital from September 2018 to February 2019. All of them underwent preoperative and postoperative transhepatic arterial contrast-enhanced ultrasonography to evaluate the therapeutic effect by observing the enhancement in tumor and drainage area. The outcomes of magnetic resonance imaging (MRI) one month after TACE were used for comparison. The results of transhepatic arterial contrast-enhanced ultrasonography and MRI were compared by the χ2 test, and the Kappa test was used to evaluate the consistency of the results of transhepatic arterial contrast-enhanced ultrasonography and MRI.

Results

The enhancement in tumor immediately after TACE was not different from the result of magnetic resonance imaging (MRI) one month after TACE (P=0.289). The enhancement in tumor and drainage area immediately after TACE was not different from the outcomes of magnetic resonance imaging (MRI) one month after TACE (P=1.000). The Kappa in observing the enhancement in tumor and drainage area was higher than that in observing the enhancement in tumor (0.780 vs 0.664, P＜0.001). The specificity, sensitivity, and accuracy in observing the enhancement in both tumor and drainage area were 84.2%, 93.1%, and 89.5%, respectively, which were higher than those in observing the enhancement in tumor alone (79.3%, 89.4%, and 83.3%).

Conclusion

Transhepattic arterial contrast-enhanced ultrasonography could observe the enhancement in tumor and drainage area immediately after TACE, and has high clinical value in evaluating the therapeutic effect of TACE.

Key words: Transhepatic arterial contrast-enhanced ultrasonography, Drainage area, Transarterial chemoembolization, Carcinoma, hepatocellular
图1 肝细胞癌患者术前及术后即刻经肝动脉超声造影图像。经肝动脉栓塞化疗（TACE）术前（图a~d）：肝右叶近被膜处可见一偏高回声结节（图a标尺处）；彩色多普勒检查示其周边部可见血流信号（图b箭头处）；经肝动脉超声造影提示5 s时结节呈均匀高增强（图c）；48 s时结节周边部可见引流区（图d箭头示）。TACE术后（图e~h）：术后即刻结节内由于栓塞剂沉积呈不均匀高增强（图e标尺处）；术后即刻经肝动脉超声造影提示4 s时结节周边部可见少量点状强化（图f箭头处）；5 s时病灶周围肝呈不均匀强化（箭头处），灌注速度较前减慢（图gΔ处）；60 s时结节周边可见引流区部分残留（图h箭头处）
图2 同一肝细胞癌患者术后1个月MRI图像。术后1个月MRI显示动脉期病灶内可见强化（图a），延迟期强化消退（图b），提示病灶仍存在活性（箭头处为目标病灶）
表1 经肝动脉超声造影仅观察瘤内和同时观察瘤内与引流区评估结果与MRI结果对比
超声造影观察范围 MRI 总计
有残留 无残留
瘤内

有残留

 23 2 25

无残留

 6 17 23
瘤内与引流区

有残留

 27 3 30

无残留

 2 16 18
合计 29 19
1
Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma [J]. Lancet, 2003, 362(9399): 1907-1917.
2
Bosch FX, Ribes J, Díaz M, et al. Primary liver cancer: worldwide incidence and trends [J]. Gastroenterology, 2004, 127(5 Suppl 1): S5-S16.
3
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update [J]. Hepatology, 2011, 53(3): 1020-1022.
4
Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study [J]. Liver Int, 2015, 35(9): 2155-2166.
5
Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival [J]. Hepatology, 2003, 37(2): 429-442.
6
Minami Y, Kudo M, Kawasaki T, et al. Transcatheter arterial chemoembolization of hepatocellular carcinoma: usefulness of coded phase-inversion harmonic sonography [J]. AJR Am J Roentgenol, 2003, 180(3): 703-708.
7
安天志, 高嵩, 靳勇, 等. 中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南 [J]. 介入放射学杂志, 2018, 27(12): 1117-1126.
8
Sakon M, Nagano H, Nakamori S, et al. Intrahepatic recurrences of hepatocellular carcinoma after hepatectomy: analysis based on tumor hemodynamics [J]. Arch Surg, 2002, 137(1): 94-99.
9
Kita R, Sakamoto A, Nagata Y, et al. Visualization of blood drainage area from hypervascular hepatocellular carcinoma on ultrasonographic images during hepatic arteriogram: comparison with depiction of drainage area on contrast-enhanced ultrasound [J]. Hepatol Res, 2012, 42(10): 999-1007.

URL    
10
Sparchez Z, Mocan T, Radu P, et al. Contrast enhanced ultrasonography in assessing the treatment response to transarterial chemoembolization in patients with hepatocellular carcinoma [J]. Med Ultrason, 2016, 18(1): 96-102.
11
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases [J]. Hepatology, 2018, 68(2): 723-750.
12
Park YN, Yang CP, Fernandez GJ, et al. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver [J]. Am J Surg Pathol, 1998, 22(6): 656-662.
13
Ueda K, Matsui O, Kawamori Y, et al. Hypervascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography [J]. Radiology, 1998, 206(1): 161-166.
14
Kitao A, Zen Y, Matsui O, et al. Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography--radiologic-pathologic correlation [J]. Radiology, 2009, 252(2): 605-614.
15
Matsui O, Kadoya M, Yoshikawa J, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization [J]. Radiology, 1993, 188(1): 79-83.
16
Terayama N, Matsui O, Gabata T, et al. Accumulation of iodized oil within the nonneoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization [J]. Cardiovasc Intervent Radiol, 2001, 24(6): 383-387.
17
Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil [J]. J Vasc Interv Radiol, 2007, 18(3): 365-376.

URL    
[1] 丁建民, 秦正义, 张翔, 周燕, 周洪雨, 王彦冬, 经翔. 超声造影与普美显磁共振成像对具有高危因素的≤3 cm肝结节进行LI-RADS分类诊断的前瞻性研究[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 930-938.
[2] 李淼, 朱连华, 韩鹏, 姜波, 费翔. 高帧频超声造影评价肝细胞癌血管形态与风险因素的研究[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 911-915.
[3] 董杰, 杨松, 杨浩, 陈翔, 张万里. 乙酰辅酶A羧化酶2基因高甲基化与肝细胞癌临床病理因素和生存期的关系[J]. 中华普通外科学文献(电子版), 2023, 17(06): 433-437.
[4] 黄威, 刘启, 陈流华, 滕茶香, 区喆建, 刘韩笑, 陈健聪, 张昆松. 新定义的可预测肝癌预后的焦亡相关lncRNA模型[J]. 中华普通外科学文献(电子版), 2023, 17(05): 357-365.
[5] 王荣昌, 欧奇峰, 黄晋杰, 王彩琴, 汪谦, 黄晓卉. miR-145-5p在肝细胞癌中的表达及其临床意义[J]. 中华普通外科学文献(电子版), 2023, 17(03): 197-202.
[6] 郑希彦, 周正, 何方平, 林志群, 杜飞, 谢琴, 王少平, 史宪杰. 代谢综合征与乙型肝炎病毒相关性肝细胞癌预后的危险因素分析[J]. 中华普通外科学文献(电子版), 2023, 17(02): 104-109.
[7] 马铭秀, 徐锋, 谢铠岭, 郭亚明, 卢潼辉, 戴朝六. 术前碱性磷酸酶-前白蛋白比值对肝细胞癌切除术预后的评估价值[J]. 中华普通外科学文献(电子版), 2023, 17(02): 99-103.
[8] 尹宏祥, 段家康, 江博文, 谈燚. 全身免疫炎症指数联合预后营养指数对接受根治性切除术的肝细胞癌的预后价值研究[J]. 中华普通外科学文献(电子版), 2023, 17(02): 93-98.
[9] 曹亚娟, 黎兵华, 余德才. 转化治疗联合Laennec入路机器人右半肝切除治疗进展期肝癌[J]. 中华腔镜外科杂志(电子版), 2023, 16(02): 116-119.
[10] 胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.
[11] 吴凤芸, 滕鑫, 刘连娟. 高帧频超声造影与增强磁共振对不同直径原发性高分化肝细胞癌的诊断价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 404-408.
[12] 刘中百, 任勇军. 肝细胞癌的介入治疗现状及进展[J]. 中华消化病与影像杂志(电子版), 2023, 13(02): 111-115.
[13] 梁伟, 王晓彬, 洪笑阳, 蔡明岳, 梁礼聪, 陈烨, 黄培凯, 刘铭宇, 林立腾, 朱康顺. 原位肝癌小鼠微波消融术后复发模型的构建[J]. 中华介入放射学电子杂志, 2023, 11(02): 133-139.
[14] 张玉冰, 陈彦晖, 沈新颖. 局部消融术联合免疫检查点抑制剂治疗肝癌的研究进展[J]. 中华介入放射学电子杂志, 2023, 11(01): 68-73.
[15] 韦慧萍, 郭瑛明, 刘桂荣, 巫宗由, 翁秋青. 超氧化物歧化酶检测在乙型肝炎病毒相关性肝病中的应用价值[J]. 中华临床实验室管理电子杂志, 2023, 11(01): 21-26.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号